Search Results - "Nenwani, Minal"

Exploiting metabolic vulnerabilities after anti-VEGF antibody therapy in ovarian cancer by Glassman, Deanna, Kim, Mark S., Spradlin, Meredith, Badal, Sunil, Taki, Mana, Bhattacharya, Pratip, Dutta, Prasanta, Kingsley, Charles V., Foster, Katherine I., Animasahun, Olamide, Jeon, Jin Heon, Achreja, Abhinav, Jayaraman, Anusha, Kumar, Praveen, Nenwani, Minal, Wuchu, Fulei, Bayraktar, Emine, Wu, Yutuan, Stur, Elaine, Mangala, Lingegowda, Lee, Sanghoon, Yap, Timothy A., Westin, Shannon N., Eberlin, Livia S., Nagrath, Deepak, Sood, Anil K.

“…Despite modest clinical improvement with anti-vascular endothelial growth factor antibody (AVA) therapy in ovarian cancer, adaptive resistance is ubiquitous…”
Get full text

Isotopically non‐stationary 13C metabolic flux analysis of two closely related fast‐growing cyanobacteria, Synechococcus elongatus PCC 11801 and 11802 by Jaiswal, Damini, Nenwani, Minal, Wangikar, Pramod P

“…SUMMARYSynechococcus elongatus PCC 11801 and 11802 are closely related cyanobacterial strains that are fast‐growing and tolerant to high light and temperature…”
Get full text

Isotopically non-stationary 13 C metabolic flux analysis of two closely related fast-growing cyanobacteria, Synechococcus elongatus PCC 11801 and 11802 by Jaiswal, Damini, Nenwani, Minal, Wangikar, Pramod P

“…Synechococcus elongatus PCC 11801 and 11802 are closely related cyanobacterial strains that are fast-growing and tolerant to high light and temperature. These…”
Get full text

Probing the metabolism of γ‐glutamyl peptides in cyanobacteria via metabolite profiling and 13C labeling by Jaiswal, Damini, Nenwani, Minal, Mishra, Vivek, Wangikar, Pramod P.

“…SUMMARY Cyanobacteria are attractive model organisms for the study of photosynthesis and diurnal metabolism and as hosts for photoautotrophic production of…”
Get full text

Probing the metabolism of γ-glutamyl peptides in cyanobacteria via metabolite profiling and 13 C labeling by Jaiswal, Damini, Nenwani, Minal, Mishra, Vivek, Wangikar, Pramod P

“…Cyanobacteria are attractive model organisms for the study of photosynthesis and diurnal metabolism and as hosts for photoautotrophic production of chemicals…”
Get full text

Devimistat in combination with gemcitabine and cisplatin in biliary tract cancer: Pre-clinical evaluation and phase 1b multicenter clinical trial (BilT-04) by Mohan, Arathi, Griffith, Kent A., Wuchu, Fulei, Zhen, David B., Kumar-Sinha, Chandan, Crysler, Oxana, Hsiehchen, David, Enzler, Thomas, Dippman, Dominique, Gunchick, Valerie, Achreja, Abhinav, Animasahun, Olamide, Choppara, Srinadh, Nenwani, Minal, Chinnaiyan, Arul M., Nagrath, Deepak, Zalupski, Mark M., Sahai, Vaibhav

Get full text

Devimistat in Combination with Gemcitabine and Cisplatin in Biliary Tract Cancer: Preclinical Evaluation and Phase Ib Multicenter Clinical Trial (BilT-04) by Mohan, Arathi, Griffith, Kent A, Wuchu, Fulei, Zhen, David B, Kumar-Sinha, Chandan, Crysler, Oxana, Hsiehchen, David, Enzler, Thomas, Dippman, Dominique, Gunchick, Valerie, Achreja, Abhinav, Animasahun, Olamide, Choppara, Srinadh, Nenwani, Minal, Chinnaiyan, Arul M, Nagrath, Deepak, Zalupski, Mark M, Sahai, Vaibhav

“…Devimistat (CPI-613) is a novel inhibitor of tumoral mitochondrial metabolism. We investigated the effect of devimistat in vitro and in a phase Ib clinical…”
Get full text

Inulin-gel-based oral immunotherapy remodels the small intestinal microbiome and suppresses food allergy by Han, Kai, Xie, Fang, Animasahun, Olamide, Nenwani, Minal, Kitamoto, Sho, Kim, Yeji, Phoo, May Thazin, Xu, Jin, Wuchu, Fulei, Omoloja, Kehinde, Achreja, Abhinav, Choppara, Srinadh, Li, Zhaoheng, Gong, Wang, Cho, Young Seok, Dobson, Hannah, Ahn, Jinsung, Zhou, Xingwu, Huang, Xuehui, An, Xinran, Kim, Alexander, Xu, Yao, Wu, Qi, Lee, Soo-Hong, O’Konek, Jessica J., Xie, Yuying, Lei, Yu Leo, Kamada, Nobuhiko, Nagrath, Deepak, Moon, James J.

“…Despite the potential of oral immunotherapy against food allergy, adverse reactions and loss of desensitization hinder its clinical uptake. Dysbiosis of the…”
Get full text

Human induced pluripotent stem cell based hepatic-modeling of lipid metabolism associated TM6SF2 E167K variant by Faccioli, Lanuza Ap, Sun, Yiyue, Animasahun, Olamide, Motomura, Takashi, Liu, Zhenghao, Kurihara, Takeshi, Hu, Zhiping, Yang, Bo, Cetin, Zeliha, Baratta, Annalisa M, Shankaran, Ajay, Nenwani, Minal, Altay, Leyla Nurcihan, Huang, Linqi, Meurs, Noah, Franks, Jonathan, Stolz, Donna, Gavlock, Dillon C, Miedel, Mark T, Ostrowska, Alina, Florentino, Rodrigo M, Fox, Ira J, Nagrath, Deepak, Soto-Gutierrez, Alejandro

“…TM6SF2 rs58542926 (E167K) is related to increased prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD). Conflicting mouse study…”
Get full text

Abstract LB163: A microfluidic platform for developing circulating tumor cells (CTCs) organoids for precision medicine in pancreatic cancer by Zhang, Yu, Smith, Scott, Nenwani, Minal, Gunchick, Valerie, Sahai, Vaibhav, Nagrath, Sunitha, Nagrath, Deepak

“…Introduction Pancreatic ductal adenocarcinoma (PDAC) is predicted to be the second leading cause of cancer death in the US by 2030. Besides the late detection…”
Get full text

Abstract 7091: Significance of the tryptophan catabolism pathway in triple-negative breast cancer shows potential targets in certain subsets relating to the serine pathway by Jeon, Jin Heon, Achreja, Abhinav, Slayton, Mark, Animasahun, Olamide, Nenwani, Minal, Paserba, Miya, Farah, Zackariah, Merajver, Sofia D., Nagrath, Deepak

“…Background: Breast cancer (BC) is the most prevalent form of cancer worldwide, encompassing 12.5% of all forms of cancers with the fifth highest mortality…”
Get full text

What’s next after bevaciumab resistance? Targeting metabolic vulnerabilities in ovarian cancer (022) by Glassman, Deanna, Kim, Mark, Badal, Sunil, Spradlin, Meredith, Animasahun, Olamide, Jeon, Jin Heon, Achreja, Abhinav, Jayaraman, Anusha, Kumar, Praveen, Nenwani, Minal, Wuchu, Fulei, Bayraktar, Emine, Wu, Yutuan, Stur, Elaine, Mangala, Lingegowda, Lee, Sanghoon, Yap, Timothy, Westin, Shannon, Eberlin, Livia Schiavinato, Nagrath, Deepak, Sood, Anil

Get full text

Abstract 2236: The role of CPI-613 in cholangiocarcinoma treatment by Wuchu, Fulei, Animasahun, Olamide, Choppara, Srinadh, Gunchick, Valerie, Nenwani, Minal, Roy, Jyotirmoy, Paserba, Miya, Achreja, Abhinav, Sahai, Vaibhav, Nagrath, Deepak

“…Cholangiocarcinoma is the second most common primary liver cancer with extremely low survival rates. However, a combination of gemcitabine and cisplatin is the…”
Get full text

Abstract 6037: Identification of collateral lethal targets in cancers using integrated machine learning and flux analysis platform for personalized metabolic therapy by Achreja, Abhinav, Jeon, Jin Heon, Slayton, Mark, Yu, Tao, Animasahun, Olamide, Nenwani, Minal, Wuchu, Fulei, Mittal, Anjali, Lu, Xiongbin, Merajver, Sofia D., Nagrath, Deepak

“…Chromosomal alterations that occur frequently in cancers confer selective advantages for tumor progression by deleting tumor-suppressing genes or amplifying…”
Get full text

Metabolic collateral lethal target identification reveals MTHFD2 paralogue dependency in ovarian cancer by Achreja, Abhinav, Yu, Tao, Mittal, Anjali, Choppara, Srinadh, Animasahun, Olamide, Nenwani, Minal, Wuchu, Fulei, Meurs, Noah, Mohan, Aradhana, Jeon, Jin Heon, Sarangi, Itisam, Jayaraman, Anusha, Owen, Sarah, Kulkarni, Reva, Cusato, Michele, Weinberg, Frank, Kweon, Hye Kyong, Subramanian, Chitra, Wicha, Max S., Merajver, Sofia D., Nagrath, Sunitha, Cho, Kathleen R., DiFeo, Analisa, Lu, Xiongbin, Nagrath, Deepak

“…Recurrent loss-of-function deletions cause frequent inactivation of tumour suppressor genes but often also involve the collateral deletion of essential genes…”
Get full text

Abstract 1092: Targeting one-carbon metabolism radiosensitizes pancreatic ductal adenocarcinoma cells (PDAC) by Nenwani, Minal, Achreja, Abhinav, Animasahun, Olamide, Sarangi, Itisam, Roy, Jyotirmoy, Choppara, Srinadh, Wuchu, Fulei, Paserba, Miya, Mittal, Anjali, Quispe, Sergio, Mohan, Aradhana, Morgan, Meredith, Lawrence, Theodore S., Nagrath, Deepak

“…One of the most challenging aspects of PDAC is intense therapeutic resistance towards radiotherapy. Cellular signaling pathways are tightly regulated to…”
Get full text